Cerulean Pharma (Nasdaq: CERU) Shares Rise on Sale Speculation

Cerulean Pharma, Inc. – Nasdaq: CERU

An announcement by the Board of Cerulean Pharma to explore strategic alternatives has sent shares higher on speculation that a sale may be in the works. CERU, traded on the Nasdaq under ticker CERU, ended trading Thursday at $0.93 and have reached a high of $1.49 in early trading on heavy volumes. The announcement was likely due to a Phase 2 clinical trial failure, in August, which led to Cerulean cutting half its workforce.

Waltham, MA-based Cerulean Pharma develops products to improve treatment options for cancer victims. The company developed the Dynamic Tumor Targeting™ Platform designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Cerulean’s lead platform-generated NDC clinical candidate, CRLX101, is in multiple clinical trials. Our lead indication is ovarian cancer. Our second platform-generated NDC clinical candidate, CRLX301, is in Phase 2a clinical development for the treatment of advanced solid tumors.

Cerulean sales peaked in 2012 when the company posted a figure of $600k. No sales were reported for 2015. CERU shares have never experienced positive EPS – losing more than $1.20 EPS in each of the past five years. CERU lost $1.56 EPS in 2015. Three firms rate CEU shares. One rates them as a “Strong Buy”, and the other rates CERU as a “Hold”. Their consensus price target is $1.50.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/3/2017
Ticker Symbol CERU
Last Price a/o 9:23 AM EST  $                      1.34
Average Volume                    328,570
Market Cap (mlns)  $                    25.49
Sales (mlns)
Shares Outstanding (mlns) 27.38
Share Float (mlns) 24.66
Shortable Yes
Optionable Yes
Inside Ownership 1.30%
Short Float 2.68%
Short Interest Ratio 2.01
Quarterly Return 24.82%
YTD Return 31.46%
Year Return -58.99%

Keryx Therapeutics (Nasdaq: KERX) Up over 15% on Heavy Volume

Keryx Biopharmaceuticals Inc. – Nasdaq: KERX

Boston, MA-based Keryx Pharmaceuticals are up over 15% on heavy volume and have gained almost 40% in the last year. KERX, traded on the Nasdaq, has an average daily volume of 1.58 million but have already traded over 2.5 million at the time of this writing.

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines that provide treatments to people with renal disease. In September 2014, the U.S. Food and Drug Administration approved Keryx’s first medicine, Auryxia tablets.

On January 12th, the company announced the publication of results from its pivotal Phase 3 study evaluating ferric citrate for iron deficiency anemia in non-dialysis-dependent chronic kidney disease in the online issue of the Journal of the American Society of Nephrology.

“The results shown in this pivotal study demonstrated that ferric citrate, if approved for this indication, could provide an important new treatment option for people living with chronic kidney disease and iron deficiency anemia who are not on dialysis,” said Steven Fishbane, M.D., chief of nephrology for North Shore University Hospital and Long Island Jewish Medical Center.

Keryx Biopharmaceuticals sales have increased each year since 2013 and posted a figure of $13.7 million in 2015. KERX shareholders have not experienced the same increase in their EPS. KERX EPS has been negative for the past five years and in 2015 KERX had an EPS loss of $1.19. Eight firms follow Keryx and five rate KERX shares as a “Hold”, one rates it as a “Buy”, and two rate KERX shares as a “Strong Buy”. Their consensus price target is $7.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/2/2017
Ticker Symbol KERX
Last Price a/o 2:33 PM EST  $                      5.39
Average Volume                1,580,000
Market Cap (mlns)  $                  506.49
Sales (mlns) $28.20
Shares Outstanding (mlns) 105.96
Share Float (mlns) 101.78
Shortable Yes
Optionable Yes
Inside Ownership 0.69%
Short Float 20.54%
Short Interest Ratio 13.21
Quarterly Return 5.99%
YTD Return -18.43%
Year Return 38.95%

BioDelivery Sciences Int’l (Nasdaq: BDSI) Gains on CEO Comments

BioDelivery Sciences International Inc. – Nasdaq: BDSI

Yesterday BioDelivery Sciences International President and CEO Mark Sirgo gave shareholders good news. Today shares (BDSI) are responding by gaining over 7% in early trading on the Nasdaq. Sirgo stated to a conference that he forecasts increasing profitability due to the reacquisition of licensing rights to Belbuca, a pain management drug. Sirgo stated “On Jan. 6, we inherited a product on very favorable financial terms that ended the year with a $30 million gross sales run rate”

BioDelivery Sciences International is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI utilizes proprietary BioErodible MucoAdhesive and other drug delivery technologies to develop and commercialize new applications of proven therapies aimed at addressing important unmet medical needs. BDSI’s marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, painful diabetic neuropathy and opioid dependence.

BDSI has increased year-on-year sales for the past three years and in 2015 BDSI reported a figure of $48.2 million. EPS for BDSI also has been improving though still negative. In 2013 EPS for BDSI was a loss of $1.51 but improved to a smaller loss of $0.72 in 2015. Seven firms follow BioDelivery Sciences. Six rate BDSI shares as a “Strong Buy” and one rates the shares as a “Hold”. Their consensus price target for BDSI is $4.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/2/2017
Ticker Symbol PLUG
Last Price a/o 8:43 AM EST  $                      2.05
Average Volume                    606,540
Market Cap (mlns)  $                  102.79
Sales (mlns) $43.80
Shares Outstanding (mlns) 54.1
Share Float (mlns) 51.34
Shortable Yes
Optionable Yes
Inside Ownership 1.10%
Short Float 8.65%
Short Interest Ratio 7.32
Quarterly Return -17.39%
YTD Return 8.57%
Year Return -52.14%

Galectin Therapeutics (Nasdaq: GALT) Announces New Financing and Clinical Milestones

Galectin Therapeutics Inc. – Nasdaq: GALT

Norcross, GA-based Galectin Therapeutics announced today that it has generated sufficient financing to cover currently planned expenditures through 2017 and it remains on track to present top line data from its NASH-CX Phase 2 clinical trial by early December 2017. Shares of Galectin Therapeutics are traded on the Nasdaq under ticker GALT.

Galectin Therapeutics is a biotechnology company that discovers and develops new therapies for fibrotic disease and cancer. Drug candidates based on their proprietary carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function. Galectin Therapeutics persues therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease.

Galectin Therapeutics has reached clinical milestones in its NASH-CX trial, a double blind, placebo-controlled Phase 2b clinical trial. To date, 47 patients have completed all 52 weeks of infusions with the company’s lead compound, GR-MD-02, and 122 patients have completed 26 weeks of infusions. In the NASH-CX clinical trial, more than 3,000 infusions (or 75% of the maximum infusions in the trial) have been administered with no drug-related serious adverse reactions. Only 8 patients have discontinued participation in the clinical trial before their scheduled completion dates, and none of the discontinuations were due to drug-related serious adverse events. Currently, the approximate 5% dropout rate is significantly below the 25% included as part of the trial design. The top-line data readout of the NASH-CX trial remains on track for early December 2017.

GALT EPS has been negative for the past five years. In 2015 GALT’s EPS loss was $0.88. Three firms follow Galectin. Two rate GALT shares as a “Hold” and one rates the shares as a “Sell”. The consensus price target for GALT is $0.75.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Mannkind Pharmaceuticals (Nasdaq: MNKD) Rises on Conference Call Expectations

Mannkind Corporation – Nasdaq: MNKD

Shares of Valencia, CA-based Mannkind Corporation gained over 10% from Monday’s close. Shares of the biotechnology company, traded on the Nasdaq under ticker MNKD, are heavily shorted and have a “short float” figure over 30%. Rumors are that today’s conference call will bring positive news for MNKD shareholders and is widely viewed as the catalyst for MNKD’s recent price rise.

MannKind Corporation is a biopharmaceutical company that discovers and develops therapeutic products for patients with diseases such as diabetes. The company dates back to February 1991, when it was incorporated as Pharmaceutical Discovery Corporation in Elmsford, New York. Mannkind’s Technosphere® formulation technology was developed at PDC shortly after its formation.  In the mid-1990s, Alfred Mann – at the time, the CEO of MiniMed Inc. – started working with PDC through a collaborative research effort and eventually became a significant shareholder.  In 2001, the company merged with two other companies owned by Alfred Mann (CTL Immunotherapies Corp. and Allecure Corp.) and the surviving company changed its name to MannKind Corporation.

Mannkind Pharmaceuticals has had no reported sales since 2011 when they posted a figure of $100,000. Since 2011, MNKD shares outstanding figures have increased annually from 121.82 million to 406.17 million in 2015. MNKD EPS has never been positive and in 2015 posted a loss of $0.91. Two firms follow Mannkind and both rate MNKD shares as a “Sell” with a consensus price target of $0.15.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/31/2017
Ticker Symbol MNKD
Last Price a/o 7:55 PM EST  $                      0.71
Average Volume                5,260,000
Market Cap (mlns)  $                  336.70
Sales (mlns) $162.40
Shares Outstanding (mlns) 478.33
Share Float (mlns) 322.75
Shortable Yes
Optionable Yes
Inside Ownership 0.20%
Short Float 30.34%
Short Interest Ratio 18.63
Quarterly Return 56.27%
YTD Return 10.57%
Year Return -36.00%

Aeterna Zentaris Inc. (Nasdaq: AEZS) Shares Up on Expectations of 2017 Developments

Aeterna Zentaris Inc. – Nasdaq: AEZS

Aeterna Zentaris shares traded up over 20% today on the belief that the company will be completed with Phase 3 testing and begin commercialization of two products in 2017. AEZS, traded on the Nasdaq, experienced volumes ten times normal in today’s trading session and the shares settled at $3.15.

Canadian-based Aeterna Zentaris has two drugs far along in its pipeline. The first is Macrilen, a drug designed to evaluate adults for growth hormone deficiency, is expected to deliver top-line results once the final stages of pivotal clinical testing are completed in early-2017. The other drug in development is Zoptrex, a treatment for advanced endometrial cancer, which has been re-engineered from an established chemotherapeutic agent. The new treatment is rumored to be safer in terms of side-effects, and reportedly provides extended chances for survival for women with advanced endometrial cancer.

AEZS shares have experienced negative EPS for the last five years but year-on-year EPS losses have been narrowing. In 2011 AEZS lost $168.75 per share. That loss narrowed to $18.18 in 2015. AEZS sales have been inconsistent and in 2015 Aeterna Zenatris posted just $500k. Two firms follow Aeterna Zentaris and both rate AEZS shares as a “Strong Buy” with a price target of $8.75.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/31/2017
Ticker Symbol AEZS
Last Price a/o 6:09 PM EST  $                      3.20
Average Volume                    279,030
Market Cap (mlns)  $                    37.55
Sales (mlns) $0.70
Shares Outstanding (mlns) 11.92
Share Float (mlns) 11.61
Shortable Yes
Optionable Yes
Inside Ownership 0.60%
Short Float 6.55%
Short Interest Ratio 2.73
Quarterly Return -17.54%
YTD Return -12.50%
Year Return 0.64%

Xoma Corp. (Nasdaq: XOMA) Rises on Proof-of-Concept

Xoma Corporation – Nasdaq: XOMA

Xoma Corporation announced, after hours, that it has established proof-of-concept for its product candidate 358 in congenital hyperinsulinism and hypoglycemia post-bariatric surgery. Berkley, CA-based Xoma is up almost 10%, on heavy volumes, in the after-hours market on the news. The regular session ended with XOMA at $4.29 and has reached $4.83 in the after-hours session.

XOMA Corporation develops therapeutic antibodies. The Company’s product candidates result from its expertise in developing ground-breaking monoclonal antibodies, including allosteric antibodies, which have created new opportunities to potentially treat a wide range of human diseases. XOMA’s scientific research has produced a portfolio of endocrine assets, each of which has the opportunity to address multiple indications.

Eric P. Brass, M.D., Ph.D. stated “These data clearly demonstrate that a single-dose of 358 results in predictable and reproducible pharmacokinetics and meaningful improvements in glucose concentrations. The Company can now assess, in follow-on studies, the consistency and magnitude of 358’s effect through multi-dose protocols to yield sustained steady-state drug exposure in the target populations.”

Xoma Corporation sales have been erratic but in 2015 Xoma posted their best results since 2011 with a figure of $$55.4 million. EPS for XOMA has been negative for the past five years, but again the smallest loss was posted in 2015 with a loss figure of $3.50. Four firms follow Xoma and all rate the shares as a “Hold” with a consensus price target of $9.50.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

 

Evok Pharma (Nasdaq: EVOK) Rises on Analyst Upgrade

Evok Pharma, Inc. – Nasdaq: EVOK

An analyst upgrade and positive social forum chatter of technical chart characteristics are pushing up shares of Evok Pharma – traded on the Nasdaq under ticker EVOK. Volumes are heavy. EVOK ended Friday at $2.48 and the shares are now trading over 10% higher in mid-afternoon action.

Solana Beach, CA-based Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI) diseases. The Company was established by pharmaceutical executives with a track record of acquiring, developing, registering, and marketing pharmaceutical products in the US. Evoke’s lead product candidate, EVK-001, is in late stage clinical testing. The product is intended for the treatment of diabetic gastroparesis.

EPS for EVOK has been negative for the past five years. In 2014 EVOK shares lost $2.20 per share and in 2015 lost $1.87. There are no reported sales for EVOK. Two analysts rate EVOK as a “Strong Buy” one rates the shares a “Buy”, one rates EVOK a “Hold”, and one rates EVOK at a “Sell”. Their consensus price target is $6.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/30/2017
Ticker Symbol EVOK
Last Price a/o 3:32 PM EST  $                      2.77
Average Volume 974,460
Market Cap (mlns)  $                    30.60
Sales (mlns)
Shares Outstanding (mlns) 12.34
Share Float (mlns) 16.45
Shortable Yes
Optionable No
Inside Ownership 32.37%
Short Float 16.45%
Short Interest Ratio 1.6
Quarterly Return 40.11%
YTD Return 22.77%
Year Return -19.22%

Chimerix Inc. (Nasdaq: CMRX) Shares Hit YTD Highs on Heavy Volume

Chimerix,Inc. – Nasdaq: CMRX

In December Chimerix Inc. shares were dropped from the Nasdaq Biotech index. Today they hit a year-to-date high of $5.63 on heavy volumes. Chimerix Inc. trades on the Nasdaq under ticker CMRX.

 Durham, North Carolina-based Chimerix is a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix is currently enrolling patients in Study 351 to provide patients with serious adenovirus infection or disease access to treatment with Chimerix’s brincidofovir. No therapy is currently approved for the treatment of adenovirus infection in immunocompromised patients. Chimerix is also working with the Biomedical Advanced Research and Development Authority (BARDA) to develop brincidofovir (CMX001) as a medical countermeasure to treat potential smallpox outbreaks in the event of bioterror attacks or accidental release.

In 2015, CMRX shares lost $2.68 EPS on reported sales of $10.8 million. Eight firms follow Chimerix Inc. One rates CMRX shares as a “Strong Buy”, six rate the shares as a “Hold”, and one rates CMRX as a “Sell”. Their consensus price target is $7. 

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/23/2017
Ticker Symbol CMRX
Last Price a/o 3:48 PM EST  $                      5.57
Average Volume 534,500
Market Cap $222.31 million
Sales $6.8 million
Shares Outstanding 45.37 million
Share Float 45.37 million
Shortable Yes
Optionable Yes
Inside Ownership 1.00%
Short Float 6.65%
Short Interest Ratio 5.64
Quarterly Return 5.38%
YTD Return 6.52%
Year Return -42.62%

Marinus Pharmaceuticals (Nasdaq: MRNS) Up on Massive Volume

Marinus Pharmaceuticals, Inc. – Nasdaq: MRNS

Massive volumes are being traded in nano-cap Marinus Pharmaceuticals. Traded on the Nasdaq under ticker MRNS, volumes are over nine times their daily average. The increased volumes appear to be in response to news of positive preliminary data from the initial CDKL5 patients enrolled in its ongoing Phase 2 open-label study evaluating its CNS-selective GABAA modulator, ganaxolone, as a treatment for orphan, genetic disorders. Marinus is currently evaluating ganaxolone in orphan pediatric indications for the treatment of genetic seizure and behavior disorders, and preparing to initiate Phase 2 studies in status epilepticus, an orphan indication, and postpartum depression.

CDKL5 is a serious and rare genetic disorder that is caused by a mutation of the cyclin-dependent kinase-like 5 (CDKL5) gene, located on the X chromosome. It predominantly affects girls and is characterized by early-onset, difficult-to-control seizures and severe neuro‑developmental impairment.

Two firms follow Marinus Pharmaceuticals. One rates MRNS as a “Strong Buy” and the other rates the shares as a “Hold”. The consensus price target for MRNS is $2.50. Shareholders of MRNS have never experienced a positive EPS and last year MRNS had an EPS loss of $1.67 on zero reported sales.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.